medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2022, Número S3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2022; 33 (S3)


Impacto de las terapias alternativas en el tratamiento de la hipertensión arterial sistémica resistente

Díaz-y-Díaz E, Parcero-Valdés JJ

Idioma: Inglés [English version]
Referencias bibliográficas: 26
Paginas: s233-237
Archivo PDF: 182.06 Kb.


RESUMEN

La hipertensión arterial resistente se ha definido como una condición en la que un paciente está siendo tratado con un régimen antihipertensivo con ≥ 4 fármacos o ≥ 3 fármacos que incluyen un diurético y todavía tiene cifras de presión arterial ≥ 140/90 mmHg. Dado que la prevalencia de la hipertensión arterial resistente es alta, los clínicos deben ser conscientes de su riesgo potencial de no manejar esta condición. Esta revisión tiene como objetivo discutir las contribuciones y las recomendaciones clínicas para ayudar a los clínicos a entender y tratar mejor la hipertensión arterial resistente dentro de todos los entornos de atención. También se muestran datos de ensayos aleatorios controlados con placebo y se concluye que la denervación renal reduce significativamente la presión arterial ambulatoria y en el consultorio. Además, fue similar entre los pacientes que tomaban o no medicamentos antihipertensivos de fondo. Asimismo, un nuevo tratamiento denominado terapia de estimulación de barorreceptores ha mostrado datos prometedores tanto en experimentos como en la clínica para manejar la hipertensión arterial resistente. Ambos enfoques pueden ser muy relevantes en pacientes que no toleran la medicación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-3104. Available in: https://doi.org/10.1093/eurheartj/ehy339

  2. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125: 1635-1642. Available in: https://doi.org/10.1161/CIRCULATIONAHA.111.068064

  3. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-1080. Available in: https://doi.org/10.1161/HYPERTENSIONAHA.111.170308.

  4. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898-902. Available in: https://doi.org/10.1161/HYPERTENSIONAHA.110.168948

  5. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012; 125: 1594-1596. Available in: https://doi.org/10.1161/CIRCULATIONAHA.112.097345

  6. Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P et al. Prevention and treatment of hypertension with algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open. 2015; 5: e008951. Available in: https://doi.org/10.1136/bmjopen-2015-008951

  7. Díaz y Díaz E. Hipertensión arterial sistémica resistente; el papel de la denervación renal. Cardiología y Medicina Vascular. Actualidades. Editorial Alfil; n.d.

  8. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009; 54: 690-697. Available in: https://doi.org/10.1161/HYPERTENSIONAHA.108.119883

  9. Leong KTG, Walton A, Krum H. Renal sympathetic denervation for the treatment of refractory hypertension. Annu Rev Med. 2014; 65: 349-365. Available in: https://doi.org/10.1146/annurev-med-051812-145353

  10. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011; 58: 559-565. Available in: https://doi.org/10.1161/HYPERTENSIONAHA.111.173799

  11. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart. 2013; 99: 1579-1587. Available in: https://doi.org/10.1136/heartjnl-2013-304238

  12. Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M et al. Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med. 2022; 34: 112-118. Available in: https://doi.org/10.1016/j.carrev.2021.01.031

  13. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021; 397: 2476-2486. Available in: https://doi.org/10.1016/S0140-6736(21)00788-1

  14. Ahmad Y, Francis DP, Bhatt DL, Howard JP. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv. 2021; 14: 2614-2624. Available in: https://doi.org/10.1016/j.jcin.2021.09.020.

  15. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018; 391: 2335-2345. Available in: https://doi.org/10.1016/S0140-6736(18)31082-1

  16. Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020; 395: 1444-1451. Available in: https://doi.org/10.1016/S0140-6736(20)30554-7

  17. Desch S, Okon T, Heinemann D, Kulle K, Rohnert K, Sonnabend M et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015; 65: 1202-1208. Available in: https://doi.org/10.1161/HYPERTENSIONAHA.115.05283

  18. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016; 34: 1639-1647. Available in: https://doi.org/10.1097/HJH.0000000000000977

  19. Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018; 391: 2346-2355. Available in: https://doi.org/10.1016/S0140-6736(18)30951-6

  20. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393-1401. Available in: https://doi.org/10.1056/NEJMoa1402670

  21. Singh RR, McArdle ZM, Iudica M, Easton LK, Booth LC, May CN et al. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension. 2019; 73: 718-727. Available in: https://doi.org/10.1161/HYPERTENSIONAHA.118.12250

  22. Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens. 2018; 31: 1156-1163. Available in: https://doi.org/10.1093/ajh/hpy108

  23. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957-967. Available in: https://doi.org/10.1016/S0140-6736(15)01225-8

  24. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021; 397: 1625-1636. Available in: https://doi.org/10.1016/S0140-6736(21)00590-0

  25. Wallbach M, Koziolek MJ. Baroreceptors in the carotid and hypertension-systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure. Nephrol Dial Transplant. 2018; 33: 1485-1493. Available in: https://doi.org/10.1093/ndt/gfx279

  26. Chunbin W, Fu S, Jing H. Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis. Clin Exp Hypertens. 2018; 40: 501-508. Available in: https://doi.org/10.1080/10641963.2016.1273943




2020     |     www.medigraphic.com